GO:0006699 bile acid biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006699 (bile acid biosynthetic process) describes the enzymatic conversion of cholesterol into bile acids, a steroid carboxylic acid class essential for lipid digestion and metabolic signaling.
• The classical pathway is initiated by CYP7A1 in the liver, while alternative pathways involve CYP27A1 and CYP8B1, generating primary bile acids cholic acid and chenodeoxycholic acid.
• Bile acids are potent signaling molecules that activate nuclear receptors FXR and membrane receptor TGR5, regulating glucose, lipid, and energy metabolism.
• Gut microbiota biotransform primary bile acids into secondary bile acids, influencing host physiology and disease susceptibility.
• Dysregulation of bile acid biosynthesis is linked to cholestasis, gallstones, non-alcoholic fatty liver disease, and metabolic disorders.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise interrogation of bile acid pathway genes in vitro and in vivo.
Description
Bile acid biosynthetic process (GO:0006699) is the metabolic pathway responsible for converting cholesterol into bile acids, a group of steroid carboxylic acids that facilitate the absorption of dietary fats and fat-soluble vitamins. This process occurs primarily in the liver and involves a series of enzymatic reactions that modify the sterol nucleus and side chain of cholesterol, yielding primary bile acids such as cholic acid (CA) and chenodeoxycholic acid (CDCA). Beyond their role in digestion, bile acids act as signaling molecules that regulate their own synthesis and modulate glucose and lipid metabolism through receptors like FXR and TGR5. The importance of this pathway extends to human health, as disruptions in bile acid biosynthesis contribute to cholestatic liver diseases, gallstone formation, and metabolic syndrome. Understanding the molecular players and regulatory mechanisms of GO:0006699 is therefore critical for developing therapeutic strategies targeting metabolic and hepatic disorders.
bile acid biosynthetic process At A Glance
| GO ID | GO:0006699 |
|---|---|
| GO term | bile acid biosynthetic process |
| Ontology | biological_process |
| Synonym | bile acid anabolism, bile acid biosynthesis, bile acid formation, bile acid synthesis |
| Major function | Conversion of cholesterol to bile acids for lipid digestion and metabolic signaling |
| Location | Primarily in liver hepatocytes, with contributions from gut microbiota |
| Key enzymes | CYP7A1, CYP8B1, CYP27A1, AKR1D1, etc. |
| Regulation | Feedback inhibition by bile acids via FXR, hormonal and circadian control |
What Is GO:0006699?
The bile acid biosynthetic process (GO:0006699) encompasses the chemical reactions and pathways that result in the formation of bile acids, which are steroid carboxylic acids found in bile. This process primarily starts with cholesterol and involves multiple enzymatic steps, including hydroxylation, oxidation, and side-chain shortening, to produce primary bile acids.
Why Is bile acid biosynthetic process Important in Cell Biology?
Bile acid biosynthesis is essential for the emulsification and absorption of dietary fats and fat-soluble vitamins, and it serves as a major route for cholesterol elimination. Additionally, bile acids function as signaling molecules that activate nuclear receptors and G-protein-coupled receptors, thereby influencing glucose homeostasis, lipid metabolism, and energy expenditure. Dysregulation of this pathway is implicated in a wide range of diseases, including cholestasis, gallstones, fatty liver disease, and metabolic syndrome, making it a key area of biomedical research.
• Facilitates digestion and absorption of dietary lipids and fat-soluble vitamins.
• Provides a major pathway for cholesterol catabolism and elimination.
• Generates signaling molecules that regulate glucose and lipid metabolism via FXR and TGR5.
• Influences gut microbiota composition and function through bile acid biotransformations.
• Dysregulation leads to cholestatic liver diseases, gallstones, and non-alcoholic fatty liver disease.
• Associated with metabolic disorders such as obesity, insulin resistance, and type 2 diabetes.
• Plays a role in drug metabolism and pharmacokinetics by affecting absorption and transport.
• Target for therapeutic interventions in liver and metabolic diseases.
What Happens During bile acid biosynthetic process?
Initiation by Cholesterol 7α-Hydroxylase (CYP7A1)
In simple terms: The first step is like opening a door: cholesterol is modified by an enzyme called CYP7A1 to start the process.
The classical (neutral) pathway begins with the hydroxylation of cholesterol at the 7α position by CYP7A1, a cytochrome P450 enzyme located in the endoplasmic reticulum of hepatocytes. This reaction is rate-limiting and commits cholesterol to bile acid synthesis. CYP7A1 expression is tightly regulated by feedback mechanisms involving bile acids and hormones.
Modification of the Steroid Nucleus
In simple terms: After the first step, the cholesterol molecule is further altered by a series of enzymes to change its shape.
Following 7α-hydroxylation, the sterol nucleus undergoes additional modifications, including 12α-hydroxylation by CYP8B1 (which determines the ratio of cholic acid to chenodeoxycholic acid) and 3β-hydroxy-Δ5-oxosteroid isomerization. These reactions are catalyzed by enzymes such as CYP8B1 and AKR1D1, leading to the formation of intermediates like 7α-hydroxy-4-cholesten-3-one.
Side-Chain Oxidation and Shortening
In simple terms: The tail of the molecule is trimmed and oxidized to produce the final bile acid structure.
The side chain of the steroid is oxidized and shortened by enzymes including CYP27A1, which catalyzes 27-hydroxylation, followed by oxidative cleavage to form the carboxylic acid group. This step is crucial for generating the mature primary bile acids, cholic acid and chenodeoxycholic acid.
Alternative (Acidic) Pathway
In simple terms: There is a backup route that starts with a different enzyme, CYP27A1, instead of CYP7A1.
The alternative pathway is initiated by CYP27A1, which hydroxylates cholesterol at the 27 position, producing 27-hydroxycholesterol. This pathway can contribute significantly to bile acid synthesis, especially under conditions where CYP7A1 activity is low, and it primarily produces chenodeoxycholic acid.
Conjugation and Secretion
In simple terms: The newly made bile acids are tagged with amino acids to make them water-soluble and then pumped out of the liver cell.
Before secretion, primary bile acids are conjugated with taurine or glycine by bile acid-CoA:amino acid N-acyltransferase (BAAT) to form bile salts, which are more water-soluble. These conjugated bile acids are then exported into bile via the bile salt export pump (BSEP/ABCB11).
Key Genes Involved in GO:0006699 bile acid biosynthetic process
The following genes encode key enzymes and regulators involved in the bile acid biosynthetic process (GO:0006699).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP7A1 | Rate-limiting enzyme initiating classical pathway | Target for cholesterol-lowering and metabolic studies |
| CYP8B1 | 12α-hydroxylase determining CA/CDCA ratio | Modulates bile acid pool composition |
| CYP27A1 | Sterol 27-hydroxylase in alternative pathway | Linked to cerebrotendinous xanthomatosis |
| AKR1D1 | Δ4-3-oxosteroid 5β-reductase | Deficiency causes bile acid synthesis defects |
| CYP7B1 | Oxysterol 7α-hydroxylase in acidic pathway | Associated with liver disease and neurosteroidogenesis |
| HSD3B7 | 3β-hydroxy-Δ5-C27-steroid oxidoreductase | Mutations cause progressive cholestasis |
| BAAT | Bile acid-CoA:amino acid N-acyltransferase | Conjugation of bile acids; deficiency leads to hypercholanemia |
| ABCB11 | Bile salt export pump (BSEP) | Mutations cause PFIC2 and cholestasis |
| NR1H4 | Farnesoid X receptor (FXR) | Master regulator of bile acid homeostasis |
| SLC10A1 | Sodium-taurocholate cotransporting polypeptide (NTCP) | Hepatic bile acid uptake |
| FGF19 | Fibroblast growth factor 19 | Intestinal FXR target that inhibits CYP7A1 |
| SHP (NR0B2) | Small heterodimer partner | Mediates feedback repression of CYP7A1 |
| TGR5 (GPBAR1) | Membrane bile acid receptor | Regulates energy metabolism and inflammation |
| VDR | Vitamin D receptor | Bile acid sensor in intestine and liver |
| PXR (NR1I2) | Pregnane X receptor | Regulates bile acid detoxification |
| CAR (NR1I3) | Constitutive androstane receptor | Modulates bile acid metabolism |
| OSTα/β | Organic solute transporter | Bile acid efflux from enterocytes |
How Is bile acid biosynthetic process Regulated?
Bile acid biosynthesis is tightly regulated by a negative feedback loop involving the nuclear receptor FXR (NR1H4). When bile acid levels rise, FXR is activated in the liver and intestine, leading to induction of SHP (NR0B2) and FGF19, which repress CYP7A1 transcription. Additionally, hormones such as glucagon and insulin, as well as circadian rhythms, influence CYP7A1 expression. The gut microbiota also modulates bile acid pool composition through deconjugation and dehydroxylation, indirectly affecting FXR signaling.
bile acid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP7A1 | Gallstone disease, hypercholesterolemia | Liver-specific KO mouse, overexpression in HepG2 |
| CYP27A1 | Cerebrotendinous xanthomatosis | Patient-derived iPSCs, knock-in mouse |
| ABCB11 | Progressive familial intrahepatic cholestasis type 2 | KO mouse, point mutation knock-in |
| NR1H4 | Metabolic syndrome, NAFLD | Tissue-specific KO, reporter knock-in |
| AKR1D1 | Bile acid synthesis defects, cholestasis | CRISPR KO in hepatocytes |
Cholestatic Liver Diseases
Defects in bile acid biosynthesis or transport can cause cholestasis, a condition characterized by impaired bile flow and accumulation of toxic bile acids in the liver. Mutations in genes such as ABCB11 (BSEP) and HSD3B7 lead to progressive familial intrahepatic cholestasis (PFIC) and other cholestatic disorders.
Metabolic Disorders
Altered bile acid signaling contributes to the pathogenesis of non-alcoholic fatty liver disease (NAFLD), obesity, insulin resistance, and type 2 diabetes. FXR and TGR5 are promising therapeutic targets for these metabolic conditions.
Gallstone Disease
Imbalances in bile acid composition, particularly cholesterol supersaturation, promote gallstone formation. Genetic variations in CYP7A1 and CYP8B1 have been associated with gallstone susceptibility.
Neurological Disorders
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in CYP27A1, leading to impaired bile acid synthesis and accumulation of cholestanol, resulting in neurological and cardiovascular symptoms.
From bile acid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Role of CYP7A1 in cholesterol homeostasis | Liver-specific CYP7A1 knockout mouse |
| Effect of FXR activation on bile acid synthesis | FXR knockout and knock-in reporter cell lines |
| Impact of point mutations in ABCB11 on bile transport | Point mutation knock-in HepG2 cells |
| Consequences of CYP27A1 deficiency | CYP27A1 knockout iPSC-derived hepatocytes |
| Overexpression of FGF19 in metabolic disease | Transgenic overexpression mouse |
| Microbiota-mediated bile acid transformation | Gnotobiotic mice with defined bacterial consortia |
How to Study the bile acid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Bile acid species and concentrations | Profiling bile acids in liver, serum, feces |
| RNA-seq | Transcript levels of bile acid genes | Assessing pathway regulation |
| ChIP-seq | FXR binding sites | Mapping FXR target genes |
| CRISPR knockout screen | Genes affecting bile acid levels | Discovery of novel regulators |
| Western blot | Protein expression of enzymes | Validating knockout or overexpression |
| Reporter assays | FXR transcriptional activity | Screening for modulators |
| 16S rRNA sequencing | Gut microbiota composition | Linking microbiota to bile acid metabolism |
Quantification of Bile Acids
Mass spectrometry (LC-MS/MS) is the gold standard for measuring bile acid species in biological samples, allowing profiling of primary and secondary bile acids. This method is essential for assessing pathway activity and diagnosing bile acid synthesis defects.
Gene Expression Analysis
RNA-seq and qPCR are used to quantify mRNA levels of genes involved in bile acid biosynthesis, such as CYP7A1, CYP8B1, and CYP27A1, providing insights into transcriptional regulation.
Enzyme Activity Assays
In vitro enzymatic assays using recombinant enzymes or liver microsomes can measure specific activities of CYP7A1, CYP8B1, and other enzymes, helping to characterize kinetic parameters and inhibitor effects.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify novel regulators of bile acid synthesis and transport, enabling unbiased discovery of pathway components.
How CRISPR Can Be Used to Study GO:0006699 bile acid biosynthetic process
Knockout
CRISPR knockout of key bile acid genes (e.g., CYP7A1, CYP27A1) in cell lines or animal models allows researchers to study loss-of-function phenotypes, such as altered bile acid pool and metabolic consequences.
Point Mutation
Introducing disease-associated point mutations (e.g., in ABCB11 or AKR1D1) via CRISPR base editing or HDR enables modeling of cholestatic disorders and testing of corrective therapies.
Knock-in
Knock-in of reporter genes (e.g., GFP) or tags into endogenous loci (e.g., CYP7A1) facilitates real-time monitoring of gene expression and protein localization in bile acid research.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of genes like FGF19 or SHP can be used to study their impact on bile acid synthesis and metabolic regulation.
How EDITGENE Supports bile acid biosynthetic process Research
Researchers studying bile acid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation or disease pathogenesis. EDITGENE provides comprehensive CRISPR-based services to create precise cellular and animal models, enabling functional validation and therapeutic target discovery.
Contact EDITGENE today to design your custom CRISPR model for bile acid biosynthetic process research.
Frequently Asked Questions About bile acid biosynthetic process
What is bile acid biosynthetic process GO:0006699?
GO:0006699 is a Gene Ontology biological process term describing the chemical reactions and pathways that convert cholesterol into bile acids, which are steroid carboxylic acids essential for lipid digestion and metabolic signaling.
What genes are involved in bile acid biosynthetic process?
Key genes include CYP7A1, CYP8B1, CYP27A1, AKR1D1, HSD3B7, BAAT, and ABCB11, among others.
Where does bile acid biosynthesis occur?
It occurs primarily in the liver, specifically in hepatocytes, with additional contributions from the alternative pathway in extrahepatic tissues.
How is bile acid synthesis regulated?
It is regulated by a negative feedback loop involving FXR, SHP, and FGF19, as well as hormones and circadian rhythms.
What diseases are associated with defects in bile acid biosynthesis?
Defects can cause cholestasis, gallstones, cerebrotendinous xanthomatosis, and metabolic disorders like NAFLD.
What is the role of gut microbiota in bile acid metabolism?
Gut bacteria deconjugate and dehydroxylate primary bile acids to form secondary bile acids, influencing host signaling and health.
How can CRISPR be used to study bile acid biosynthesis?
CRISPR knockout, knock-in, and overexpression models enable functional studies of bile acid genes in vitro and in vivo.
What are primary and secondary bile acids?
Primary bile acids (cholic acid, chenodeoxycholic acid) are synthesized in the liver; secondary bile acids (deoxycholic acid, lithocholic acid) are formed by gut microbiota.
Why is bile acid biosynthesis important for metabolism?
Bile acids activate FXR and TGR5, regulating glucose and lipid metabolism, energy expenditure, and inflammation.
What methods are used to study bile acid biosynthesis?
LC-MS/MS, RNA-seq, enzyme assays, and CRISPR screens are commonly used to measure bile acids and study pathway regulation.
Conclusion
The bile acid biosynthetic process (GO:0006699) is a fundamental metabolic pathway with far-reaching implications for digestion, metabolism, and disease. Advances in CRISPR-based models and analytical techniques continue to unravel the complex regulation and signaling roles of bile acids, offering new therapeutic opportunities for liver and metabolic disorders.
References
- 1. Winston JA et al.. 2020. Diversification of host bile acids by members of the gut microbiota.. Gut Microbes 11(2):158-171 PMID: 31595814
- 2. Cai J et al.. 2022. Bile acid metabolism and signaling, the microbiota, and metabolic disease.. Pharmacol Ther 237:108238 PMID: 35792223
- 3. Chiang JY. 2013. Bile acid metabolism and signaling.. Compr Physiol 3(3):1191-212 PMID: 23897684
- 4. Li T et al.. 2014. Bile acid signaling in metabolic disease and drug therapy.. Pharmacol Rev 66(4):948-83 PMID: 25073467
- 5. Ramírez-Pérez O et al.. 2017. The Role of the Gut Microbiota in Bile Acid Metabolism.. Ann Hepatol 16(Suppl. 1: s3-105.):s15-s20 PMID: 29080339
- 6. Chiang JYL et al.. 2022. Discovery of farnesoid X receptor and its role in bile acid metabolism.. Mol Cell Endocrinol 548:111618 PMID: 35283218
- 7. Ridlon JM et al.. 2016. Consequences of bile salt biotransformations by intestinal bacteria.. Gut Microbes 7(1):22-39 PMID: 26939849
- 8. Danielsson H et al.. 1975. Bile acid metabolism.. Annu Rev Biochem 44:233-53 PMID: 1094911
